

אוגוסט 2026

רופא/ה נכבד/ה
רוקח/ת נכבד/ה,

הריני להודיעכם כי העלון לרופא של התכשיר עודכן:

Upstaza

אפסטזה

Solution for infusion

מרכיב פעיל : eladocagene exuparvovec

התוויה מאושרת :

Upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype.

להלן העדכונים בעלון לרופא המהווים החמרות (הוספה בכחול):

4.8 Undesirable effects

Summary of the safety profile

The safety information was observed in 3 open-label clinical studies in which eladocagene exuparvovec was administered to 30 AADC-deficient patients aged 19 months to 8.5 years at the time of dosing. Patients were followed for a median duration of 59.3 months (minimum of 11.8 months to a maximum of 5.7 years). Twenty-sevensix patients treated in the clinical studies enrolled in a long-term follow-up study. The duration of follow-up from the time of gene therapy ranged from 51.627-2 to 126.5 months (approximately 4.32 to 10.5 years).

The most common adverse reaction was dyskinesia; it was reported in 26 (86.7%) patients and was prevalent during the first 2 months post-treatment.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Table 5 Cumulative number of subjects achieving new-PDMS-2 motor milestones (Mastery) at month 24, month 60, and month 96 (Studies AADC-010, AADC-011, and AADC-1602; N=22)

Motor Milestone/ Month	Number of Subjects (%)		
	Month 24	Month 60	Month 96
Full head control	14 (64)	17 (77+6-73)	17 (77+6-73)

Medison Pharma Ltd.

10 Hashiloach St., P.O.B 7090, Petach-Tikva 4917002 Israel

Tel. +972. 3. 925. 0250, Fax. +972. 3. 922. 5740

medisonpharma.com

Sitting unassisted	11 (50)	15 (68)	16 (73)
Standing with support	8 (36)	11 (50)	11 (50)
Walking with assistance	2 (9)	<u>7 (32)</u> 6 (27)	<u>9 (41)</u> 7 (32)

PDMS-2 total score

PDMS-2 total score was measured as a secondary endpoint throughout the clinical studies. PDMS-2 maximal scores are 450-482, depending on age (<12 months or > 12 months). All subjects treated with eladocagene exuparvovec showed increases from baseline in mean PDMS-2 total scores over time, with some benefit observed as early as 3 months (Figure 3). ~~At the 24-month timepoint, the~~ least squares (LS) mean of change from baseline in PDMS-2 total score was 77.9, 111.6, 138.2, and 144.3 points ~~at Month 12, Month 24, Month 60, and Month 96, respectively.~~ Improvement from baseline in PDMS-2 total score was as early as 12, Month 24, Month 60, and Month 96 timepoints, respectively (77.6 points) and was maintained to 60, months (139.0 points) and Month 96 timepoints, respectively (141.6 points). Patients who receive eladocagene exuparvovec at a younger age demonstrate a faster treatment response and appear to reach a higher final level.

The following data were collected as secondary endpoints in the clinical studies.

Cognitive and communication skills

Bayley-III, a standard assessment of cognition, language, and motor development for, infants and toddlers (1-42 months of age), was utilized in Studies AADC-010 and AADC-011 to assess cognitive and language development. The language subscale consists of receptive and expressive communications.

Over time, all subjects showed gradual and sustained increases in mean cognitive and total language scores, which is the combined score for receptive and expressive communication scores. The mean raw total score for cognitive subscale at baseline was 12.41 (N=22). The LS mean change from baseline in cognitive score showed an increase of 12.3 at Month 12, 16.4 at Month 24, 23.36 at Month 60, and 25.0 at Month 96. The mean raw total score for language subscale at baseline was 18.09 (N=22). The LS mean change from baseline in total language score showed an increase of 7.96 at Month 12, 10.41 at Month 24, and 15.014.9 at Month 60, and 17.8 at Month 96.

העלון לרופא נמצא בקישור, וכן מפורסם במאגר התרופות שבאתר משרד הבריאות, וניתן לקבלו מודפס על ידי פניה לבעל הרישום.

בברכה,

מדיסון פארמה בע"מ